SGMO

Sangamo Therapeutics Inc

• TipRanks·5d ago

  Sangamo Therapeutics: Partnering-Driven Path to 2027 Fabry Gene Therapy Launch Supports Buy Rating and $10 Target

• TipRanks·04/01 06:06

  Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty

• TipRanks·04/01 00:06

  Sangamo Biosciences Balances Fabry Progress With Cash Risk

• Benzinga·03/31 17:05

  12 Health Care Stocks Moving In Tuesday's Intraday Session

• TipRanks·03/31 15:40

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)

• Benzinga·03/31 12:05

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• Benzinga·03/31 08:50

  Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket

• Seeking Alpha·03/30 22:22

  Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks

• Benzinga·03/30 21:05

  12 Health Care Stocks Moving In Monday's After-Market Session

• TipRanks·03/30 20:14

  Sangamo reports Q4 EPS (11c), consensus (5c)

• Reuters·03/30 20:13

  Sangamo publishes corporate presentation highlighting neurology genomic medicines pipeline, Fabry BLA progress

• TipRanks·03/30 20:12

  Sangamo sees FY26 operating expenses $8M

• Reuters·03/30 20:11

  Sangamo Q4 revenue misses analyst expectations

• Dow Jones·03/30 20:10

  *Sangamo Therapeutics Sees Cash and Cash Equivalents, Offering Proceeds Funding Planned Ops Into 3Q >SGMO

• Dow Jones·03/30 20:09

  *Sangamo Therapeutics Expects Oper Expenses of $120 M to $140 M in 2026 >SGMO